Followers | 17 |
Posts | 4299 |
Boards Moderated | 0 |
Alias Born | 04/13/2016 |
Saturday, February 18, 2017 9:22:27 AM
Entogenetics is using gene sequences from the black widow spider, while KBLB and most others are using sequences from the Golden Orb spider. KBLB's patent rights only cover Golden Orb spider silk, not that of Black Widow spiders. I don't know much about the stretch/strain curves of Black Widow silk.
The video was recent -- November 18, 2016 (had to search for the date). According to Prof. Brigham, they haven't achieved homozygosity in their silkworms yet. I'm guessing he recently used CRISPR/CAS instead of whatever method he was using previously.
If KBLB's experience and that of others proves true, he has a way to go before he has a stable genetic line.
I've not seen data that spider silk is 5 times tougher than Kevlar. Most of the reports I've looked at report a factor of about 3.
The pad he was showing is not a shoot pack. The ones KBLB is making for the Army are 18 inches square. A small pad like the one he showed will test better than larger pads, especially if you are only looking at penetration and not at backface signature depth.
Entogenetics has a big Mulberry tree farm already, but they do not seem to be producing large quantities of spider silk. Nevertheless, KBLB should feel a little more pressure to get out there to market.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM